HENLIUS HLX14 two products approved for market by the U.S. FDA

阿斯達克財經網
2025.09.01 14:44
復宏漢霖 (02696.HK) 公佈，收到美國食品藥品管理局「FDA」批准 HLX14(地舒單抗，美國商品名：BILDYOS 以及 BILPREVDA) 兩個產品的生物製品許可申請，用於特定人羣骨質疏鬆症治療等 8 項適應症。上市之後，集團累計已有六款產品於海外獲批上市。
Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.